Melissa Johnson: Thrilled to help launch SCRI Oncology Partners’ LinkedIn page!

Melissa Johnson, Director of Lung Cancer Research at Sarah Cannon, shared a post by SCRI Oncology Partners on LinkedIn, adding:

“Thrilled to help launch SCRI Oncology Partners’ LinkedIn page!! Building an oncology practice isn’t easy, but we are blessed to have an amazing team!!

From physician to front office staff, infusion and research RNs, laboratory personnel, MAs, and palliative care services, we are united and resolute: our goal is to bring full-service, cutting-edge cancer therapies to our patients with a compassionate and personalized approach. Stay tuned to meet more team members….”

Quoting SCRI Oncology Partners’ post:

“With our new LinkedIn page, we would like to gradually introduce the members of SCRI Oncology Partners.

First, is Dr. Melissa Johnson.
Director, Lung Cancer Research Program;
Associate Director, Drug Development.

Dr. Johnson is a medical oncologist whose research focus is new drug development for patients with lung cancer. In 2021, Dr. Johnson assumed the role of director of the Lung Cancer Research Program for Sarah Cannon Research Institute, where she supervises the lung cancer clinical trial portfolio across the Sarah Cannon network. Johnson is the co-leader of the Immune Effector Cell Therapies program, and has directed the development of the Solid Tumor Cellular Therapy program in the Drug Development Unit in Nashville.

Prior to joining Sarah Cannon, Johnson was an Associate Professor at Northwestern University and Feinberg School of Medicine. She earned her medical degree from the University of Pennsylvania. After completing residency in internal medicine at New York Hospital/Weill Cornell Medical Center, she did her fellowship training at Memorial Sloan Kettering Cancer Center where she served one year as chief fellow. She is board-certified in internal medicine and medical oncology.”

Source: Melissa Johnson/LinkedIn and SCRI Oncology Partners/LinkedIn